Dauricine Overcomes Osimertinib Resistance in Lung Cancer by Inducing Ferroptosis via Stabilizing SAT1
Cancer Science · 2025
DOI: 10.1111/cas.70113 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Biying Men und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Drug Resistance, Neoplasm, Acrylamides, Benzylisoquinolines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Southern Medical University, National Key Research and Development Program of China.
Abstract (Originalsprache)
Osimertinib is a third‐generation EGFR tyrosine kinase inhibitor (TKI) widely used to treat advanced nonsmall cell lung cancer (NSCLC) with EGFR mutations. However, resistance to osimertinib frequently develops, limiting its long‐term effectiveness. In this study, we used osimertinib‐resistant lung cancer cell lines and lung cancer patient‐derived organoids to demonstrate the potential of dauricine, a bioactive compound derived from menispermum dauricum, to overcome osimertinib resistance in lung cancer cells. Mechanistic studies reveal that dauricine, when combined with osimertinib, efficiently induces ferroptosis in resistant lung cancer cells. Notably, RNA interference and pharmacological inhibition assays identify SAT1, a key enzyme involved in polyamine metabolism and oxidative stress regulation, as a critical mediator of the synergistic effects observed with the dauricine‐osimertinib combination therapy. Furthermore, we show that dauricine can directly interact with and stabilize SAT1 to enhance its activity. In vivo, when administered with osimertinib, dauricine significantly suppresses tumor growth in osimertinib‐resistant lung cancer models. These findings provide novel insights into the role of SAT1 in overcoming osimertinib resistance and suggest that combining dauricine with osimertinib could be a promising therapeutic strategy to improve the efficacy of EGFR‐TKI therapy in resistant NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
- Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
ORCID-Profile: Shuan Rao
Förderung
- National Natural Science Foundation of China
- Southern Medical University
- National Key Research and Development Program of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- Guangzhou Municipal Science and Technology Bureau
- China Postdoctoral Science Foundation
Zitieren
APA
Men, B., Chen, Z., Ge, H., Yang, Z., Yun, L., Jiang, J., Dian, M., He, Y., Zhou, Z., Zhang, R., Yan, T., Li, Z., Zhang, Y., He, Y., He, J., Rao, X., & Rao, S. (2025). Dauricine Overcomes Osimertinib Resistance in Lung Cancer by Inducing Ferroptosis via Stabilizing SAT1. Cancer Science. https://doi.org/10.1111/cas.70113
Vancouver
Men B, Chen Z, Ge H, Yang Z, Yun L, Jiang J, et al. Dauricine Overcomes Osimertinib Resistance in Lung Cancer by Inducing Ferroptosis via Stabilizing SAT1. Cancer Science. 2025. doi:10.1111/cas.70113
BibTeX
@article{Men2025,
author = {Men, Biying and Chen, Zhijie and Ge, Haotian and Yang, Zhuoying and Yun, Liang and Jiang, Jianjun and Dian, Meijuan and He, Yujing and Zhou, Zehao and Zhang, Ruihao and Yan, Tianbao and Li, Zichao and Zhang, Yingxin and He, Yongjie and He, Junming and Rao, Xuguang and Rao, Shuan},
title = {Dauricine Overcomes Osimertinib Resistance in Lung Cancer by Inducing Ferroptosis via Stabilizing SAT1},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.70113}
}
EUVIMED